Kornimate/medical-research-clean huggingface dataset:
th effects of aubagio on brain pathology in multiple sclerosis studied over 12 months

Conditions: Multiple Sclerosis

Summary: this study will evaluate the effects of aubagio on changes in the brain using mri.

patients who take aubagio will have an mri, eye test, have blood taken, and complete a questionnaire on environmental risk factors to evaluate changes in the brain and on disease progression. a healthy control group will also complete the same testing regimen.

Eligibility criteria:
inclusion criteria: * subjects aged 18-65 * clinically definite ms according to the polman criteria, 52 * relapsing ms or healthy control (no neurological disorders) * expanded disability status scale (edss) scores ≤5.5 * disease duration \<30 years * normal kidney function (creatinine clearance \>59 ml/min) (patients only) * signed informed consent * none of the exclusion criteria exclusion criteria: * ms patients with hepatic impairment * nursing mothers or pregnant women who will need to undergo 12 months follow-up * women of childbearing potential not using reliable contraception * patients currently treated with leflunomide * serum alanine aminotransferase (alt) \>1.5 times the upper limit of normal * a clinically significant infectious or neurological (for hc only) illness (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days prior to treatment assignment * unwillingness or inability to comply with the requirements of this protocol including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the study protocol * any other reasons that, in the opinion of the investigator, indicate that the subject is unsuitable for enrollment into this study * other pathology related to mri abnormalities

Keywords: multiple sclerosis relapsing remitting mri teriflunomide aubagio gray matter atrophy gray matter pathology
exploratory study to explore the safety and efficacy of the hdx therapy using theranova 500 dialyzer in comparison to hemodiafiltration

Conditions: End Stage Renal Disease

Summary: today it is well established that middle molecules comprise several compounds that are not effectively removed by high-flux dialyzers, and effective clearance of large middle molecules in the process of dialysis depends on the dialyzer membrane having large enough pore sizes, larger than the conventional high-flux dialyzers. studies have found associations between levels of large middle molecule uremic toxins and immune dysfunction and inflammation, as well as adverse outcomes. this indicates that dialysis membranes having larger pores, enabling an expanded hd (hdx) with more effective removal of large middle molecules, can have a positive impact on the inflammatory state. while data is starting to appear on the long-term use of the hdx therapy, little is still known on how large middle molecules and inflammation markers are affected over time.


Eligibility criteria:
inclusion criteria: * esrd patients age between 18 - 80 years * clinically stable as judged by the treating physician for 30 days prior to enrollment, as demonstrated by pertinent patient medical history, physical examination, and laboratory testing * hemodialysis therapy with hdf for at least 3 months immediately prior to study enrollment exclusion criteria: * no informed consent provided * significant psychiatric disorder, mental disability, or other condition that may interfere with the patient's ability to provide informed consent * pregnant, breastfeeding, or planning to become pregnant * unstable vascular access associated with risk of low and variable extracorporeal blood flow rate (qb) * chronic liver disease, known paraprotein-associated disease, known bleeding disorders (e.g., gastrointestinal bleed, colonic polyps, small bowel angiodysplasia and active peptic ulcers) * major bleeding episode (i.e. soft tissue bleeding, blood in stool, joint damage, retinal bleeding, extensive mucosal bleeding, exsanguination, cerebral hemorrhage) ≤ 12 weeks prior to enrollment * blood (red blood cell) transfusion ≤ 12 weeks prior to enrollment * clinical signs of acute infection ≤ 4 weeks prior to enrollment * active cancer, except for basal cell or squamous cell skin cancer * positive serology test for human immunodeficiency virus or hepatitis infection * scheduled for planned interventions requiring hospitalization \> 1 week * scheduled for living-donor transplantation within the study period * currently participating in another interventional clinical study or has participated in another interventional clinical study in the past 3 months that may interfere with this study
observational study on effectiveness and safety of integrative korean medicine treatment for inpatients with sciatica due to lumbar intervertebral disc herniation

Conditions: Sciatica Due to Intervertebral Disc Disorder; Intervertebral Disc Displacement; Sciatica; Sciatic Radiculopathy

Summary: observational study on the effectiveness and safety of integrative korean medicine treatment for inpatients with sciatica due to lumbar intervertebral disc herniation

establishment of a korean medicine inpatient treatment registry of inpatients with sciatica due to lumbar intervertebral disc herniation with or without spinal stenosis, in conjunction with an observational study to the aim of evaluating the effectiveness and safety of korean medicine treatment for inpatients

Eligibility criteria:
inclusion criteria: 1. lumbar intervertebral disc herniation as confirmed by a doctor of medicine or a doctor of korean medicine through an mri taken within 3 years 2. patients with radiculopathy (ipsilateral or bilateral radiculopathy) 3. patients whose pain intensity of back pain or radiating leg pain is nrs≥5 4. patients aged 19 to 70 5. patients who have agreed to participate in the clinical study and given written informed consent 6. patients admitted to a korean medicine hospital for treatment exclusion criteria: 1. patients who have been diagnosed with a serious disease that may cause low back pain or neck pain (e.g. spinal metastasis of tumor, acute fracture, spinal dislocation) 2. patients admitted due to pain caused by traffic accidents 3. patients with progressive neurological deficit or severe neurological symptoms such as spinal cord injury 4. patients with severe mental illness 5. patients with difficulty or refusal to give sign written informed consent 6. patients for whom the researchers judge participation in the clinical study to be difficult 7. diagnosis of lumbar spondylolisthesis of meyerding ⅱ or higher by a doctor of medicine or doctor of korean medicine through x-ray or mri

Keywords: integrative korean medicine treatment effectiveness safety lumbar intervertebral disc herniation
en bloc transurethral resection of non-muscle invasive bladder cancer

Conditions: Non-muscle Invasive Bladder Cancer

Summary: aim: to compare the surgical method of en bloc resection to the conventional transurethral resection of non-muscle invasive bladder cancer (nmibc) in terms of complete removal of tumour, specimen quality, and pathological certainty. background: nmibc is a common disease with a 5-year recurrence rate reported as high as 64%. the cornerstone in the treatment of nmibc is transurethral resection (turb) where the tumour is dissected in pieces, removed from the bladder, and pathologically examined for potential muscle invasion. as the tumour is fragmented before removal, the method violates basic oncological principles and compromises pathological examination. hence, turb is possibly part of the mechanism causing recurrences. en bloc resection (ebr), where the tumour is removed in toto, can potentially overcome the flaws of conventional turb, but large randomized trials are needed. methods: this project will be a multicentre randomised controlled clinical trial comparing ebr to conventional turb. patients with suspected nmibc tumours with largest tumour diameter ≥1cm and ≤6cm will be randomised to either the intervention group, thus undergoing ebr, or the control group, undergoing conventional turb. the investigators intend to include 220 patients in total, 110 patients in each group. the rct will be initiated in 2022. perspectives: if ebr can be shown to remove bladder tumours with better pathological quality and certainty, this could potentially spare patients from undergoing surgeries in the future, thereby reducing costs for both patients and society.


Eligibility criteria:
inclusion criteria: * demographics: all bmi, smokers and non-smokers * primary, papillary, non-solid bladder tumour visualised by flexible cystoscopy * tumour diameter measured on ct-scan ≥2cm ≤6cm at largest diameter * ability to fully comprehend the information provided and comply with protocol * signed consent form * patients with multiple tumours can be included if it seems feasible to resect them in one procedure exclusion criteria: * clinically suspected muscle invasive bladder cancer (invasion in to bladder muscle or extravesical extension visible on ct or solid tumour without papillary elements seen at cystoscopy) * tumour located in a bladder diverticulum * investigating physician concludes that en bloc resection is not technically possible * pregnancy

Keywords: en bloc turb
"alcohol based hand sanitizers for the prevention of acute diarrheal disease and acute respiratory infection in children under 5 attending childcare centers in bogotá, cundinamarca and tolima, in colombia: a cluster randomized control trial"

Conditions: Acute Diarrheal Disease; Acute Respiratory Infection

Summary: the purpose of this study is to conduct a randomized control trial (rct) in a developing country setting in order to evaluate the role of alcohol based hand sanitizers (abhs) in preventing the transmission of infectious diseases in areas where water is a scarce resource. the investigators want to find out if the use of abhs reduces the incidence of two leading causes of morbidity and mortality in children under 5 years of age in the developing world: acute diarrheal disease (add) and acute respiratory infections (ari).

we performed a cluster, rct in child care centers located in six urban settings of colombia with intermittent tap water availability. a total of 1727 children between 1 and 5 years of age distributed in 42 childcare centers participated in the study. the intervention consisted on installation of abhs gel dispensers and training on their use by participating children in child care centers. centers assigned to the control group were recommended to continue with current hand hygiene practices. child care centers matched by location, size and sanitary conditions were randomly assigned to intervention or control. cases of acute diarrheal disease (add) and acute respiratory infections ari were identified through teacher reported signs and symptoms of disease and validated by a trained physician. we also monitored adverse events potentially related to abhs. to compare incidence rates between study arms we modeled the number of episodes of add and ari per child using a cox proportional hazards multiple regression with random effects.

Eligibility criteria:
inclusion criteria: * children between 1 and 5 years of age * attending child care centers with limited tap water availability exclusion criteria: * chronic conditions * not willing to participate

Keywords: health production government policy; regulation; public health government policy; provision and effects of welfare programs gastrointestinal diseases respiratory tract infections diarrhea ethanol child, preschool handwashing
effectiveness of dmf and its impact on pros in suboptimal ga responders with rms

Conditions: Relapsing Forms of Multiple Sclerosis

Summary: the primary objective of the study is to estimate the annualized relapse rate (arr) over a 12-month period in patients with relapsing forms of multiple sclerosis (ms) who are treated with dimethyl fumarate (dmf) after suboptimal response to glatiramer acetate (ga). the secondary objectives of this study in this study population are to assess the impact of dmf over a 12-month period on patient-reported outcomes (pros) and health economic-related outcomes and to evaluate additional clinical outcomes at month 12.


Eligibility criteria:
key inclusion criteria: * have the ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information in accordance with national and local patient privacy regulations. * have the ability to read and understand written english. * have access to the internet and are able to complete online assessments on a computer * have a relapsing form of multiple sclerosis and satisfy the approved therapeutic indication for dimethyl fumarate (dmf) per the united states prescribing information (uspi). * are being treated for relapsing forms of multiple sclerosis (ms) with glatiramer acetate (ga) but, per the prescribing physician, have a suboptimal response (e.g., suboptimal efficacy, intolerance, or poor adherence) to ga or have stopped treatment with ga for relapsing forms of ms as a result of suboptimal response within 30 days of enrollment. * have decided to initiate treatment with dimethyl fumarate (dmf) under routine clinical care. the decision to initiate treatment with dmf must precede enrollment. * have a complete blood count (cbc) available within 6 months of initiation of treatment with dimethyl fumarate (dmf). key exclusion criteria: * are unwilling or unable to comply with study requirements, or, are deemed unsuitable for study participation at the discretion of the prescribing physician. * have major comorbid conditions that would preclude their participation in the study as determined by the prescribing physician. * have a history of malignancy. (patients with basal cell carcinoma that has been completely excised prior to study entry remain eligible.) * have a history of and/or current serious infections. * are pregnant or breastfeeding, or are planning to become pregnant or breastfeed. * are receiving concomitant disease modifying therapies other than glatiramer acetate (ga) or have initiated treatment with a new disease-modifying therapy since discontinuation of glatiramer acetate (ga). * are currently enrolled in any other clinical studies, with the exception of the dimethyl fumarate (dmf) pregnancy registry. * have received prior treatment with dimethyl fumarate (dmf). note: other protocol defined inclusion/exclusion criteria may apply
finacea 15% and brimonidine 0.33% gel in the treatment of rosacea - a pilot study

Conditions: Acne Rosacea

Summary: the pilot study will investigate whether combination treatment of finacea 15% gel and brimonidine 0.33% gel could be more effective than brimonidine 0.33% gel monotherapy in treating both the papules/pustules and erythema associated with rosacea.

acne rosacea is a chronic inflammatory disease with different components including inflammatory lesions (papules/pustules), erythema and telangiectasia. brimonidine 0.33% gel primarily affects the erythematous components of rosacea. as such, combination treatment with a standard rosacea treatment, such as finacea 15% gel, may provide additional relief for the inflammatory component of rosacea.

Eligibility criteria:
inclusion criteria: * male or female * 18 years of age and older * female subjects of childbearing potential must have a negative urine pregnancy test at baseline * female subjects of childbearing potential must practice a reliable method of contraception throughout the study * moderate or severe rosacea with an investigator global assessment (iga) score of 3 or 4 * able to understand and comply with the requirements of the study and sign informed consent/health insurance portability and accountability authorization forms exclusion criteria: * female subjects who are pregnant, breast feeding or who are of childbearing potential and not practicing a reliable method of birthcontrol * history of hypersensitivity or idiosyncratic reaction to any component of the test medications * subjects who have not completed the proper wash-out periods for prohibited medications and/or procedures * medical condition that contraindicates the subject's participation in the study * alcohol or drug abuse is evident within the past 5 years * history of poor cooperation, non-compliance with medical treatment, unreliability * participation in an investigational drug study within 30 days of the baseline visit
aprepitant for chemotherapy induced nausea and vomiting in chinese advanced non-small cell lung cancers

Conditions: Carcinoma, Non-small Cell Lung

Summary: aprepitant is an oral neurokinin-1(nk-1) antagonist which is widely used for the prevention of chemotherapy-induced nausea and vomiting(cinv), it is metabolized by cyp34a, however, up to now it was still unknown the cinv control rate of aprepitant in chinese non-small cell lung cancer(nsclc) patients, we hypothesis that cyp3a4 and nk-1 polymorphism would influence aprepitant plasma concentration, which may lead to the individual difference of cinv control rate.

patients pathologic diagnosed of advanced non-small cell lung cancer, according to nccn non-small cell lung cancer guide line(2014 v2),the patient should receive standard platinum based chemotherapy, are randomized divided into two groups, aprepitant group and placebo group. in aprepitant group, patients would receive aprepitant 125 mg at day1, then 80 mg at day2 and day3. in placebo group, patients would receive placebo from day1 to day3. in both group, dexamethasone and 5-ht inhibitor palonosetron were give at the same dose. during the treatment, any grade of nausea and vomiting should be recorded in order to evaluate the complete response rate of cinv, other side-effects should be recorded. in aprepitant group, plasma should be taken for the analyze of plasma concentration, gene polymorphism of cyp3a4 and nk-1 should be analyzed for all the patients who received aprepitant if possible.

Eligibility criteria:
inclusion criteria: * patients pathologic diagnosed of advanced non-small cell lung cancer * according to nccn non-small cell lung cancer guide line(2014 v2), patients are suitable for platinum based chemotherapy. exclusion criteria: * patients could not receive platinum based chemotherapy judged by clinical doctors * pregnancy or breast-feeding women * any serious disease which could not be controled * urine protein≥++, or 24h urine protein\>1g * less than 18 years old or more than 75 years old

Keywords: aprepitant non-small cell lung cancer
high flow nasal cannula in immunocompromised patient with acute respiratory failure

Conditions: High Flow Nasal Cannula; Non Invasive Ventilation; Acute Respiratory Failure

Summary: this study will be conducted in ain shams university hospital in the general intensive care unit after ethical committee approval number (fmasu r 9/2020) .it is a prospective randomized controlled study. eligible patients will be randomized by computer system to one of two groups either high flow nasal oxygen (hfno) group or non invasive ventilation (niv) group. inclusion criteria includes admitted immunocompromised patients to our general 34 beds icu with acute hypoxemic respiratory failure (arf).

arf is characterized by respiratory rate more than 25/min, pao2/fio2 less than 300 under standard o2 10 l/min, or findings of persistent pulmonary infiltrates in radiographs. immunocompromised patients have one or more of the following criteria hematological malignancy (either active or remitting in the last 5 years), bone marrow transplantation (in the last 5 years), severe leucopenia less than 1000 white blood cells in cubic millimeter, solid organ transplantation, steroid therapy more than 0.5 mg/kg/day for at least 3 weeks, or cytotoxic therapy for non malignant disease. patients included in the study will be randomized after admission to icu to one of two groups, hfnc group or niv group. patients enrolled in hfnc group will receive immediate connection to hfnc with a flow of 60l/min, and fio2 adjusted to have spo2 of 92% or more, through a heated humidifier and a oxygen blender of the same machine. in case of patient intolerance to high flow, flow will be diminished to the highest tolerated by the patient. patients will be encouraged to have their mouth closed during hfnc to augment positive end expiratory pressure (peep) created by high flow.niv group, patients will be connected to icu ventilator on niv mode for at least 4 hours, through a niv continuous positive airway pressure (cpap)mask with ventilator settings; pressure support (ps) level of 8 cmh2o and peep level of 5 cmh2o,which can be increased to 10 cmh2o

Eligibility criteria:
inclusion criteria: * . inclusion criteria includes admitted immunocompromised patient to icu with acute hypoxemic respiratory failure (arf). * hematological malignancies. * post bone marrow transplantation exclusion criteria: * need of emergency intubation. * patient with deterioration of conscious level with hypoxemia with fio2 less than 90% in spite of maximum o2 support. * hemodynamic instability with need of vasoconstrictor support.

Keywords: high flow nasal cannula, . non invasive ventilation
topical cbd scar healing study

Conditions: Paramedian Forehead Flap

Summary: cbd has anti-inflammatory properties, and it interacts with skin receptors that help keep the skin healthy. this is why, investigators are looking into using cbd oil on forehead scars to see if it makes scars look better.

investigators are planning to evaluate the subjective and objective impact of cbd oil on scar healing outcomes, specifically focusing on postoperative scars resulting from paramedian forehead flap reconstruction. the study will employ a split-scar randomized control trial with established outcome measurement tools. prospective participants undergoing this procedure will be enrolled, with the vertical forehead scar as the primary area of interest. participants will be randomly assigned to one of two groups: the control group, which will receive treatment with a silicone patch only, or the experimental group, which will receive a combination of cbd oil and a silicone patch. the allocation of treatment to the top or bottom vertical half of the scar will be randomized for each patient. participants will be monitored for a duration of 6 months, during which they will complete the modified patient and observer scar assessment scale at each postoperative visit. after the 6-month period, a blinded rater will evaluate photographs of the scars using the scar cosmesis and rating scale, without knowledge of the treatment received.

Eligibility criteria:
inclusion criteria • patients that are adults (18+) of all genders and ethnicities who have undergone a pmff (paramedian forehead flap) will be considered for this study. exclusion criteria * patients younger than 18 years of age * patients with known allergies to cbd termination criteria • there will be immediate termination from the study if any allergic response to the cbd/silicone combination occurs or if the topical application of cbd/silicone significantly worsens the scar outcome at the follow up 2 visit or at any subsequent visit. ii. if the patient voluntarily requests cessation in the study.

Keywords: cbd oil